Syndax Halted Axatilimab Trial for Pulmonary Fibrosis
The drug failed to meet its primary endpoint in a 26-week clinical study of 145 patients.
Updated on Oct. 12, 2026 in Biotech
Live Poll
Do you believe clinical trial results are a reliable indicator for making personal investment decisions?
Syndax Pharmaceuticals discontinued the development of its drug axatilimab for the treatment of idiopathic pulmonary fibrosis. The decision followed a Phase 2 clinical trial that failed to meet its primary efficacy endpoint.
Why it matters
The failure marks a significant setback for the company as it attempted to expand the use of axatilimab beyond its current approved indication. The development underscores the high failure rate in repurposing existing therapeutics for complex lung diseases.
The trial measured the annualized rate of decline in forced vital capacity, defined as the total volume of air a patient can forcefully exhale after a deep breath. Despite the failure to reach efficacy goals, the drug maintained a safety and tolerability profile consistent with previous studies.
The players
Syndax Pharmaceuticals
A New York-based biotechnology firm focused on developing therapies for oncology and graft-versus-host disease.
The details
The study utilized forced vital capacity — the total volume of air a patient can exhale forcefully after a deep breath — as the primary metric for tracking lung function decline. Researchers monitored this rate over a 26-week period to determine if axatilimab could slow the progression of idiopathic pulmonary fibrosis. Axatilimab remains FDA-approved for the treatment of chronic graft-versus-host disease, an immune-mediated condition where donor cells attack the recipient's body.
Timeline
October 12, 2026: Syndax Pharmaceuticals shares dropped in after-hours trading.
The Tech Race
The abandonment of this trial marks a departure from the clinical success previously achieved with the FDA approval of axatilimab for chronic graft-versus-host disease. Syndax must now pivot its resource allocation away from respiratory indications to focus on its established hematological portfolio.
Investors reacted to the announcement as Syndax Pharmaceuticals shares fell 13% to $14.45 in after-hours trading on October 12, 2026. Because the drug remains in clinical development for other conditions, the impact is currently limited to the company’s pipeline and market valuation.
The takeaway
The failure of this trial highlights the challenges of extending drug utility to secondary indications like pulmonary fibrosis. Watch for the company's next quarterly filing to see how the discontinued development program impacts overall R&D spending and resource allocation.
Further reading
For more on the current landscape of therapeutic development, explore our Biotech section.
Live Poll
Do you believe clinical trial results are a reliable indicator for making personal investment decisions?
